The FDA announced it approved the injectable dual incretin agonist tirzepatide to improve glucose response in adults with type 2 diabetes in addition to diet and exercise.
Tirzepatide (Mounjaro, Eli Lilly) is a first-in-class medicine that activates both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, which leads to improved glucose control. Tirzepatide is injected once weekly, with the dose adjusted as tolerated to meet blood glucose goals.
“Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval of